Supplementary text Structural conservation of MIF4G domains.
A global pair-wise structure comparison (DaliLite, http://www.ebi.ac.uk/Tools/dalilite/) of UPF2 MIF4G-1 and MIF4G-2 domains with other MIF4G domain structures of eIF4G, CBP80, UPF2 MIF4G-3 and MIF4Gdb (PDB accession codes 1HU3, 1H6K, 1UW4 and 2I2O respectively) (Bae, 2010; Kadlec, 2004; Marcotrigiano, 2001; Mazza, 2001) indicates that core MIF4G domains share a similar overall fold with RMSDs between 2.0 and 4.0 Å, despite low sequence identity of between 10 and 23% (Supplementary Table 3 , Supplementary Figure S4B ). UPF2 MIF4G-1 has the highest structural similarity to eIF4G MIF4G domain (CD RMSD 2.9 Å, residues 752-986, 13% identity), whereas MIF4G-2 is most similar to MIF4G-3 (CD RMSD 2.5 Å, residues 768-983, 16% identity) (Supplementary Table 3 ). The identity in primary sequence does not correlate with the similarity in the structure, in agreement with the observation that structure-based alignments do not show any strictly conserved residues in MIF4G domains with the exception of the FIGEL motif (see below). Rather, they contain a pattern of hydrophobic residues important for interhelical packing (Kadlec, 2004) . The structural comparison also shows a conservation of the position of the helices, with the exception of the N-terminal four-helix bundle of MIF4Gdb. The helix length is also generally conserved, with the exception of UPF2 MIF4G-1 helices h9 and h10 which are elongated (Supplementary Figure S4B) . In contrast, the loops connecting the helices vary considerably. UPF2 MIF4G-1 and CBP80 contain an additional helix inserted between helices h8 and h9 and helices h9 and h10 respectively. All MIF4G domains share a conserved 'FIGEL' sequence motif on helix h6, with the hydrophobic residues being involved in interhelical packing and the glutamic residue pointing to the exterior (Kadlec, 2004; Letunic, 2002) . In MIF4G-1, the glycine residue is mutated into an alanine (268-FIAEL-272), while the canonical motif is present in MIF4G-2 (669-FIGEL-673). In UPF2 2 UPF2 MIF4G domains structure and function Clerici et al.
MIF4G-1 and MIF4G-2, the exposed glutamic residue of the FIGEL motif is involved in the binding of the capping helix hA: in MIF4G-1, Glu271 establishes a salt bridge with Arg141 of helix hA ( Figure 2A) ; in MIF4G-2, Glu672 interacts with helix hA forming a hydrogen bond with the hydroxyl group of a conserved tyrosine, Tyr468 ( Figure 3A ). In the light of these observations, we re-examined the context of the first, canonical, MIF4G domain of human CBP80. The ten helices of this domain are followed by a long proline-rich linker (residues 245-308), containing three short helices, which completely encircles the domain (Figure 1 of (Mazza, 2001 ) and Supplementary Figure S12A ) making many specific contacts with it (Supplementary Figure S12B) . Some regions of this linker make analogous interactions to that observed in the UPF2 MIF4G-2 structure. In particular Asp133 of the 'FIGEL' motif (129-FLSDL-134 in human CPB80) makes a hydrogen bond with Tyr253 of the linker (Supplementary Figure S12B ). Thus, it seems possible to distinguish two categories of MIF4G domains. On one hand those such as the MIF4G domains of eIF4G, MIF4Gdb and UPF2 MIF4G-3 which are stable as 'naked' canonical MIF4G domains. On the other hand, those where the interhelical packing is stabilised by peptide extensions to the core domain, perhaps to limit flexibility of the helical bundle, such as the first two MIF4G domains of UPF2 and that of CBP80. Very recently, the structure of the MIF4G domain of Not1 has been published as part of the yeast Ccr4-Not complex (Basquin, 2012; Fabian, 2013; Petit, 2012) .
This shows another example of stabilisation of the core helical fold by N-and C-terminal extensions that wrap around the helices.
Materials and Methods
Protein expression, purification and crystallisation DNA fragments encoding his-tagged UPF2(121-1031), UPF2(121-486), UPF2(455-757) and UPF2(455-1054) were cloned into the pProExHTb expression vector (Invitrogen).
Plasmids were transformed into E. coli BL21Star(DE3), and the cells grown overnight at 20°C after induction with 1 mM IPTG. The proteins were purified by immobilised Ni 2+ affinity chromatography. After His-tag removal using TEV protease (leaving a Gly-Ala-MetGly extension at the N-terminus), the UPF2 constructs were loaded a second time onto a Ni 2+ column. The last purification step included size exclusion chromatography (Superdex 200) in 20 mM Tris pH 7, 150 mM NaCl and 2 mM DTT followed by concentration of the proteins.
Crystallisation trials were performed with a Cartesian robot which makes 100nl+100nl drops, and positive hits conditions were refined by the hanging-drop vapour diffusion technique.
UPF2-MIF4G-1 (121-486) crystals were obtained in 100 mM bicine pH 9, 100 mM NaCl, 11% PEG 6000 and at a protein concentration of 16 mg/ml; UPF2 MIF4G-2 (455-757) crystals were obtained in 100 mM MES pH 6.0, 19% PEG 3350 and at a protein concentration of 8 mg/ml; UPF2 MIF4G-2/MIF4G-3 (455-1054) crystals were obtained in 100 mM HEPES pH 7.0, 100 mM NH 4 SO 4 , 200 mM NaKHPO 4 pH 7, 840 mM sodium malonate, 1% w/v PEG MME 2K and at a protein concentration of 10 mg/ml. Expression of seleno-methionine labelled MIF4G-1, MIF4G-2 and MIF4G-2/MIF4G-3 was carried out in E. coli BL21Star(DE3) growing in M9 minimal medium. Thirty minutes before induction (1 mM IPTG) the cells were supplemented with a cocktail of aminoacids containing selenomethionine (final concentration 60 mg/l). The labelled proteins were purified and crystallised in the same conditions as the native ones.
Crystallographic data collection and structure determination
Crystallographic statistics are given in Supplementary Table I. All data collection was performed at 100K at the European Synchrotron Radiation Facility with crystals being briefly soaked in a solution containing mother liquor and 20% glycerol as cryoprotectant and snapfrozen into liquid nitrogen. The data were integrated with XDS (Kabsch, 2010) and analysed with CCP4i. Molecular replacement was performed with PHASER (McCoy, 2007) , model building with COOT (Emsley, 2010) and refinement with REFMAC5 (Murshudov, 1997; Vagin, 2004) . As molecular replacement with previously known MIF4G domains did not work, the structures of both MIF4G-1 and MIF4G-2 were solved de novo by selenomethionine (SeMet) SAD, using SHELXD (Sheldrick, 2008) to find sites and SHARP (De la Fortelle, 1997) for refinement and phasing. For the MIF4G-1 structure, the SeMet data was the best quality and therefore used for refinement. For the low resolution combined MIF4G-2/MIF4G-3 domain structure, molecular replacement using PHASER (McCoy, 2007) using the individual domains, gave a unambiguous unique solution with log likelihood gain (LLG) of 220. This was confirmed by correspondence of predicted methionine positions with anomalous difference peaks using data from MIF4G-2/MIF4G-3 crystals grown with SeMet.
Due to the low resolution, no further refinement was performed.
Generation of the quasi-atomic UPF-EJC model
Starting from the EM reconstruction of the UPF-EJC complex (EMD-2048) and the corresponding quasi-atomic model (Melero, 2012) , we replaced the UPF2 MIF4G domains and the UPF3b RRM domain by our crystal structure of MIF4G-1 domain and by the MIG4G-2/3/UPF3b RRM complex. We used Chimera (Pettersen, 2004) to obtain the best correlation coefficient for the placement of the domains into the density. To avoid a clash with MIF4G-1 and MIF4G-2 (both are larger than the MIF4G homology model used in the original atomic model), the EJC had to be moved by 14 Å away from UPF2. Similarly, the 5 UPF2 MIF4G domains structure and function Clerici et al. Figure S7) .
UPF1 CH-domain was moved by 5 Å away from UPF2 MIF4G-3 (Supplementary
The figures were generated in PyMOL (DeLano Scientific). In the rendering of the cryo-EM map, the density cutoff was set for the display of the envelope to represent ~130% of the a priori estimated volume.
In vivo NMD assays
The E-globin 4MS2 plasmid construct and the transfection control (wt300+e3) for the tethering assay were described previously (Gehring, 2005; Gehring, 2003) . HeLa cells were grown in DMEM and transfected by calcium phosphate precipitation in 6-well plates with 0.8 μg of MS2-UPF2 fusion constructs, 0.5 μg of the control plasmid, 2 μg of the 4MS2 reporter plasmid, and 0.5 μg of a GFP expression plasmid. Total RNA was extracted with TRI Reagent (Sigma) and analyzed by northern blotting as described (Gehring, 2005; Gehring, 2003) . Signals were quantified using a Typhoon Trio (GE Healthcare) and percentages ± standard deviations were calculated from three independent experiments. For UPF2 localisation HeLa cells were transfected with 600 ng of pCI-mVenus-UPF2
plasmids. Cells were plated on coverslips 24 hours post transfection. 48 hours after transfection cells were fixed with 3.7% formaldehyde. Images were recorded on a FV1000
confocal microscope (Olympus).
Immunoprecipitation, immunoblotting and antibodies
SDS-polyacrylamide gel electrophoresis and immunoblot analysis was performed using protein samples derived either from TRI Reagent extractions ( Figure 5D ) or from lysates (RIPA buffer supplemented with protease inhibitor) of parallel transfections ( Figure   5B ). For coimmunoprecipitation UPF2 mutants were expressed as FLAG-tagged proteins in HeLa cells. Fusion proteins were immunoprecipitated with FLAG-beads (Sigma-Aldrich) and co-purified proteins analysed by immunoblotting. The antibodies against tubulin (T6074) and FLAG (F7425) were from Sigma, the antibody against V5 (18870) was from QED Bioscience, the antibody against GFP (ab290) was from Abcam and the antibodies against UPF1 and UPF2 were kindly provided by Jens Lykke-Andersen. UPF3B antiserum was raised in rabbits by Eurogentech against a C-terminal fragment of UPF3B (300-483) and affinity purified.
SMG1 purification
SMG1 was expressed and purified as described in (Izumi, 2010) with some modifications. Lysed cells in SMG1 buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl 2 , 0.5 mM DTT, 0.05% tween-20, 5% glycerol) supplemented with protease and phosphatase inhibitors (Roche) were ultracentrifuged at 100 000x g for 30 minutes. The supernatant was mixed with streptavidin beads and incubated for 2 hours at 4 °C with mixing.
After washing with SMG1 buffer containing 100 mM NaCl and then 500 mM NaCl, SMG1
was eluted with SMG1 buffer with 1.5 mM biotin. Subsequently, SMG1 was concentrated and applied on a Superose-6 column equilibrated with SMG1 buffer. The fractions corresponding to monomeric SMG1 were pooled, concentrated, snap-frozen and stored at -80 °C.
SMG1 kinase assay
0.2 μg of SMG1 were mixed with 1 μg of either UPF1-FL, UPF2 (121-486), UPF2
(455-757) or UPF2 (761-1054) in SMG1 buffer containing 2 mM DTT, 5 mM MnCl 2 and 5 mM ATP. The mixture was incubated 1 h at room temperature. Proteins were separated on 12 % SDS-PAGE gels first stained with Pro-Q Diamond Staining (Life Technologies) and then with Coomassie staining. The Pro-Q stained gel was revealed with a Typhoon scanner using 532 nm and 580 nm as excitation and emission wavelength, respectively.
Surface Plasmon Resonance
SPR experiments were performed on a BIAcore 3000 using SA sensor chips (GEHealthcare). One flow-cell was not functionalized to be used as a background control. The second flow-cell was functionalized with purified SMG1 to a density of about 2000 RU. The running buffer was 20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM MgCl 2 , 0.5 mM DTT, 0.05% Tween-20. UPF2/UPF3b solutions were injected at 25 μl/min during 3 or 4 min followed by a 10 min dissociation phase. The surfaces were regenerated by 1 minute injection of 0.5 M and 1 M NaCl solutions. The data were analyzed with the Biacore evaluation software by subtracting both the control flow cell and the buffer injection curve. The apparent equilibrium dissociation constants (K D-app ) were determined using RU values 10 seconds before the end of 8 UPF2 MIF4G domains structure and function Clerici et al.
the association phase for all curves (RU max ). These RU max were plotted as a function of protein concentration and fitted assuming a one binding site model.
Phosphosites identification by mass spectrometry
500 μg of UPF2 (761-1054) in SMG1 buffer containing 2 mM DTT, 5 mM MnCl 2 and 5 mM ATP were mixed with or without 10 μg of SMG1. The mixtures were incubated 5 h at room temperature. UPF2 and SMG1 were then separated using a Superose-6 column equilibrated with SMG1 buffer containing 500 mM NaCl. The peak corresponding to UPF2 was collected and concentrated to 100 μl. Samples were then diluted with 50mM NH 4 HCO 3 to obtain 20 μL of 0.5 μg/μl of protein , which was reduced with DTT (50 mM, 2 μL) for 30 min at 56 °C and alkylated with iodacetamide (110 mM, 2μL) for 20 min at room temperature in the dark. Incubation with trypsin (0.1 μg enzyme/10 μg protein) was carried out overnight at 37 °C. Digestion was stopped by adding 4 μl of 10% trifluoracetic acid. Prior to analysis by liquid chromatography -mass spectrometry (LC-MS/MS), the peptides were diluted to 0.1 μg/μl with 0.1% formic acid. Peptides were separated using the nanoAcquity UPLC system (Waters) fitted with a trapping (nanoAcquity Symmetry C18, 5μm, 180 μm x 20 mm) and an analytical column (nanoAcquity BEH C18, 1.7μm, 75μm x 200mm). The outlet of the analytical column was coupled directly to an LTQ Orbitrap Velos (Thermo Fisher Scientific) using the Proxeon nanospray source. The mass spectrometric raw data was processed using MaxQuant (version 1.1.1.36) (Cox, 2008 5 ' 15 ' 30 ' 60 ' 120 ' M 0 ' 5 ' 15 ' 30 ' 60 ' Figure S3 . A. Helices h9 and h10 of UPF2 MIF4G-1 form an elongated coiled-coil structure protruding away from the domain. Hydrophobic residues involved in helices h9 and h10 packing are depicted as sticks. B. Detailed view of the interaction between MIF4G-1 helix h8i with its N-and C-terminal loops and helices h6, h8 and h10. Residues involved in the packing are depicted as sticks. C. MIF4G-1 domain represented in the same orientations as in figure 1C . D. Coomassie-stained SDS-PAGE of total lysate (non induced and induced), soluble and insoluble fractions of UPF2 MIF4G-2/3 constructs with MIF4G-2 helices hA-hB and disordered linker (constructs 455-1054) and without showing that In the absence of helices hA and hB the solubility of UPF2 MIF4G-2/3 is reduced. Figure S5 . A. Anomalous difference map (orange mesh) of selenomethionine substituted UPF2 MIF4G-2/MIF4G-3 domains (contoured at 3.5 V indicating the position of the methionine residues (depicted as sticks). B. Detailed view of the anomalus difference map in the MIF4G-2/MIF4G-3 interaction region; methionine residues are labeled.
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